Alice in wonderland syndrome: Down the rabbit hole of VigiBase®

Alice in Wonderland Syndrome (AIWS) is a neurological disorder involving visual and perceptual distortions, such as altered size perception, sensations of levitation, and time distortion. Initially linked to migraines and epileptic seizures, AIWS has been associated later with tumors, infections, and both illicit and prescribed drugs. This study explores drug-related AIWS cases in the WHO global pharmacovigilance database, VigiBase®, with a focus on age-specific patterns. We queried VigiBase® for AIWS reports until December 15, 2024 and categorized them into pediatric and adult groups. Disproportionality analyses identified drug-AIWS associations using the lower bound of the confidence interval of the Information Component (IC<sub>025</sub>). We conducted sensitivity analyses, with a focus on healthcare professionals reports and excluding COVID-19 cases. We identified 87 AIWS cases: 26 (29.9 %) pediatric and 45 (51.7 %) adult. Most (64.4 %) were serious, with recovery documented in 79.6 %. COVID-19 vaccines, montelukast, and aripiprazole were most frequently reported. Montelukast showed the strongest signal in both adults (IC 4.2[3.2-5.0]) and children (IC 3.2[1.7-4.2]), followed by methylphenidate in pediatric cases (IC 2.3[0.3-3.5]). Adults showed signals for sertraline (IC 3.4[2.1-4.4]), topiramate (IC 3.1[1.3-4.2]), and aripiprazole (IC 2.1[3.5-4.4]). Signal consistency was confirmed by both sensitivity analyses. This study sheds light on age-dependent profiles of drug-associated AIWS. Montelukast, aripiprazole, sertraline, and topiramate were disproportionately associated, consistent with prior case reports. Clinicians should consider AIWS when visual distortions arise during such treatment, particularly in youths treated with methylphenidate or montelukast. While typically reversible, AIWS warrants clinical awareness and careful risk-benefit assessment. As causality cannot be established, further population-based studies are needed to confirm these findings.

Authors

Institutions

Publication Details

Journal
Psychiatry Research
Published
2025-12-21
DOI
https://doi.org/10.1016/j.psychres.2025.116920
Citations
2
Primary Topic
Face Recognition and Perception
Type
article
Field-Weighted Citation Impact
2.86
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Alice in wonderland syndrome: Down the rabbit hole of VigiBase®

Susanne Thümmler, Thibaud Lavrut, Alexandre Gérard, François Montastruc et al.
2 citations
Psychiatry Research
Face Recognition and Perception
2.86
article

Alice in wonderland syndrome: Down the rabbit hole of VigiBase®

Susanne Thümmler, Thibaud Lavrut, Alexandre Gérard, François Montastruc, Diane Merino, Faredj Cherikh, Milou-Daniel Drici, Florence Askenazy
article en
2 citations

Abstract

Alice in Wonderland Syndrome (AIWS) is a neurological disorder involving visual and perceptual distortions, such as altered size perception, sensations of levitation, and time distortion. Initially linked to migraines and epileptic seizures, AIWS has been associated later with tumors, infections, and both illicit and prescribed drugs. This study explores drug-related AIWS cases in the WHO global pharmacovigilance database, VigiBase®, with a focus on age-specific patterns. We queried VigiBase® for AIWS reports until December 15, 2024 and categorized them into pediatric and adult groups. Disproportionality analyses identified drug-AIWS associations using the lower bound of the confidence interval of the Information Component (IC<sub>025</sub>). We conducted sensitivity analyses, with a focus on healthcare professionals reports and excluding COVID-19 cases. We identified 87 AIWS cases: 26 (29.9 %) pediatric and 45 (51.7 %) adult. Most (64.4 %) were serious, with recovery documented in 79.6 %. COVID-19 vaccines, montelukast, and aripiprazole were most frequently reported. Montelukast showed the strongest signal in both adults (IC 4.2[3.2-5.0]) and children (IC 3.2[1.7-4.2]), followed by methylphenidate in pediatric cases (IC 2.3[0.3-3.5]). Adults showed signals for sertraline (IC 3.4[2.1-4.4]), topiramate (IC 3.1[1.3-4.2]), and aripiprazole (IC 2.1[3.5-4.4]). Signal consistency was confirmed by both sensitivity analyses. This study sheds light on age-dependent profiles of drug-associated AIWS. Montelukast, aripiprazole, sertraline, and topiramate were disproportionately associated, consistent with prior case reports. Clinicians should consider AIWS when visual distortions arise during such treatment, particularly in youths treated with methylphenidate or montelukast. While typically reversible, AIWS warrants clinical awareness and careful risk-benefit assessment. As causality cannot be established, further population-based studies are needed to confirm these findings.

Psychiatry ResearchVol. 356
Centre Hospitalier Universitaire de Nice (FR), Fondation Lenval (FR), Pharmacochimie et Biologie pour le Développement (FR)
Good health and well-being
Openalex Percentile: Top 8%
Face Recognition and Perception
2.86
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.